TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10690513

Group type: EXPERIMENTAL
Intervention: HuM195 treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HuM195 treatment after RA alone
Number of subjects: 27

Group type: COMPARATOR
Intervention: RA alone (historical control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HuM195 treatment in newly diagnosed APL
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HuM195 treatment in second or third remission
Number of subjects: 27
Study: 9327292

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8402132

Group type: EXPERIMENTAL
Intervention: Imipenem prophylaxis
Number of subjects: 411

Group type: COMPARATOR
Intervention: Cefuroxime plus metronidazole (control)
Number of subjects: 411
Study: 2872055

Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg
Number of subjects: 10
Study: 30028484

Group type: EXPERIMENTAL
Intervention: High-protein enteral diet providing 3 g ß‐glucan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo diet with 3 g maltodextrin
Number of subjects: 40
Study: 26975233

Group type: EXPERIMENTAL
Intervention: Proximal adenomas only
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: Multiple proximal adenomas
Number of subjects: 2430
Study: 24756009

Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg/day) plus metadoxine (500 mg three times daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prednisone (40 mg/day)
Number of subjects: 70
Study: 22322966

Group type: EXPERIMENTAL
Intervention: Topical α‐2 agonist brimonidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Goal‐directed intravenous administration of 5% albumin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Goal‐directed administration of lactated Ringer's solution
Number of subjects: 60
Study: 20196184

Group type: EXPERIMENTAL
Intervention: Lithium treatment (6-9 months)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Long-term lithium treatment
Number of subjects: 39
Study: 17929072

Group type: EXPERIMENTAL
Intervention: 1-34PTH + raloxifene
Number of subjects: 42

Group type: COMPARATOR
Intervention: raloxifene alone
Number of subjects: 42
Study: 16183427

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg) plus insulin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Insulin alone (control)
Number of subjects: 52
Study: 12955901

Group type: EXPERIMENTAL
Intervention: Novel antipsychotic drugs
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional medication
Number of subjects: 80
Study: 10727880

Group type: EXPERIMENTAL
Intervention: co-artemether alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: mefloquine alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: combination of co-artemether and mefloquine
Number of subjects: 42
Study: 8855983

Group type: EXPERIMENTAL
Intervention: IL-2, 3 x 10(6) IU m‐2 day‐1, subcutaneously for 3 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: IL-2, 5.4 x 10(6) IU m‐2 day‐1, subcutaneously for 3 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: IL-2 with levamisole (50 mg t.d.s. p.o. on days 1-3 on alternate weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: IL-2 without levamisole
Number of subjects: 39
Study: 1643799

Group type: EXPERIMENTAL
Intervention: Human Insulin (HI)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Porcine Insulin (PI)
Number of subjects: 8
Study: 6592321

Group type: EXPERIMENTAL
Intervention: Prophy-Jet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rubber cup and prophylaxis paste
Number of subjects: 0
Study: 31214914

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 2733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2733
Study: 30575489

Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 2000
Study: 27798337

Group type: EXPERIMENTAL
Intervention: GOS + 0.2 g 2'‐FL/L
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: GOS + 1.0 g 2'‐FL/L
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Breastfed
Number of subjects: 317

Group type: COMPARATOR
Intervention: Control formula (GOS only)
Number of subjects: 317
Study: 25312197

Group type: EXPERIMENTAL
Intervention: Demodex folliculorum positive patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: Demodex folliculorum negative patients
Number of subjects: 180
Study: 22076016

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) measurement of the triple marker panel of cardiac troponin I (cTnI), myoglobin, and CK-MB on admission and 90 min from admission.
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Central laboratory testing for biomarkers (control group).
Number of subjects: 1125
Study: 20061328

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) capsules, 1240 mg eicosapentaenoic acid and 1000 mg docosahexaenoic acid, for 5-7 days prior to surgery and post-operatively until hospital discharge
Number of subjects: 170

Group type: COMPARATOR
Intervention: Olive oil capsules for 5-7 days prior to surgery and post-operatively until hospital discharge
Number of subjects: 170
Study: 18672751

Group type: EXPERIMENTAL
Intervention: Robert Jones Bandage
Number of subjects: 48

Group type: COMPARATOR
Intervention: U splint
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 15983231

Group type: EXPERIMENTAL
Intervention: Arg72Thr variant of PYY
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Arg allele of PYY
Number of subjects: 84
Study: 12433819

Group type: EXPERIMENTAL
Intervention: R (ritonavir) 400 mg given simultaneously with S (saquinavir) 800 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: N (nelfinavir) 750 mg given simultaneously with S (saquinavir) 800 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: R (ritonavir) 400 mg
Number of subjects: 18
Study: 10725786

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (2 mg/kg/day) for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7795774

Group type: EXPERIMENTAL
Intervention: 2.5% selenium sulfide lotion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 1% selenium sulfide shampoo
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nonmedicated control shampoo
Number of subjects: 54
Study: 1954072

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for 11 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Digoxin 1 mg alone (control)
Number of subjects: 10
Study: 7007474

Group type: EXPERIMENTAL
Intervention: Preseasonal intranasal short ragweed (SRW) immunotherapy, sprayed SRW solutions intranasally six times a day for 12 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preseasonal intranasal short ragweed (SRW) immunotherapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment with nebulized solutions containing buffer or histamine
Number of subjects: 33
Study: 31402321

Group type: EXPERIMENTAL
Intervention: Letrozole plus taselisib (4 mg orally, on a 5 days-on, 2 days-off schedule for 16 weeks)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Letrozole plus taselisib
Number of subjects: 334

Group type: COMPARATOR
Intervention: Letrozole plus placebo
Number of subjects: 334
Study: 28647383

Group type: EXPERIMENTAL
Intervention: Agaricus bisporus mushrooms (226 g)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Meat (28 g)
Number of subjects: 32
Study: 25210140

Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine with 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and alum
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine
Number of subjects: 98
Study: 22809633

Group type: EXPERIMENTAL
Intervention: Single 2.0mm conventional titanium miniplate (Group-I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single 2.0mm three-dimensional titanium miniplate (Group-II)
Number of subjects: 20
Study: 21083671

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 4 weeks (n = 28)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 19305326

Group type: EXPERIMENTAL
Intervention: Tampon Test
Number of subjects: 0
Study: 17680954

Group type: EXPERIMENTAL
Intervention: Cell saver group (processed shed autologous blood and homologous blood if necessary)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-cell saver group (transfused homologous blood only)
Number of subjects: 49
Study: 15058123

Group type: EXPERIMENTAL
Intervention: Single-use SoftSeal laryngeal mask (n = 99)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Reusable LMA Classic laryngeal mask (n = 100)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Single-use SoftSeal laryngeal mask
Number of subjects: 200

Group type: COMPARATOR
Intervention: Reusable LMA Classic laryngeal mask
Number of subjects: 200
Study: 11498488

Group type: EXPERIMENTAL
Intervention: Zinc and Vitamin A supplementation
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Combined Zinc and Vitamin A
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 11045875

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9346980

Group type: EXPERIMENTAL
Intervention: Intervention group with moderated fat intake (25 to 30 E%)
Number of subjects: 848

Group type: COMPARATOR
Intervention: Control group with free diet
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Thin children (mean relative weight ≤ 5%)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Tall children (mean relative height ≥ 95%)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Obese children (mean relative weight ≥ 95%)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Thin children
Number of subjects: 848
Study: 8478410

Group type: EXPERIMENTAL
Intervention: Propentofylline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 4035228

Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30779339

Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 35 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 105 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 210 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 210 mg every 28 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 210 mg every 14 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 210 mg every 7 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157)
Number of subjects: 2
Study: 30011053

Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional plate osteosynthesis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 26156560

Group type: EXPERIMENTAL
Intervention: Vitamin K1 (phylloquinone) 10 mg/day for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24909155

Group type: EXPERIMENTAL
Intervention: MS Coat One F (MSC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nanoseal (NAN)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer (TMD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer PowerGel (GLU)
Number of subjects: 50
Study: 22673254

Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 73

Group type: COMPARATOR
Intervention: Physician-directed weaning
Number of subjects: 73
Study: 20119859

Group type: EXPERIMENTAL
Intervention: Bilberry juice
Number of subjects: 62

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 62
Study: 18606034

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 3

Group type: COMPARATOR
Intervention: Developmental Education for Families (control intervention)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Comparison group (children who have never been in foster care)
Number of subjects: 3
Study: 16078928

Group type: EXPERIMENTAL
Intervention: Trima Accel
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Amicus Crescendo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MCS Plus
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Donor preference
Number of subjects: 51
Study: 12417283

Group type: EXPERIMENTAL
Intervention: apo A‐I <1.2 g/l
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: apo B > or =1.4 g/l
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: apo B/apo A‐I ratio > or =1
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: non‐Hispanics
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: high density lipoprotein cholesterol
Number of subjects: 507
Study: 10420248

Group type: EXPERIMENTAL
Intervention: Bracket removing pliers
Number of subjects: 507

Group type: COMPARATOR
Intervention: Lift off debonding instrument (LODI)
Number of subjects: 507
Study: 7745931

Group type: EXPERIMENTAL
Intervention: High cholecystoenteric anastomosis with transhepatic drain (group I)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Precision anastomosis (group II)
Number of subjects: 187
Study: 2200382

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/d)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg every 12 hours)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Verapamil sustained release (240 mg/d)
Number of subjects: 394
Study: 31563659

Group type: EXPERIMENTAL
Intervention: Awake sedation with target controlled propofol infusion
Number of subjects: 47

Group type: COMPARATOR
Intervention: Alprazolam premedication only
Number of subjects: 47
Study: 30472337

Group type: EXPERIMENTAL
Intervention: 0.075% capsaicin lotion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 27799019

Group type: EXPERIMENTAL
Intervention: IPS plus WPFM
Number of subjects: 107

Group type: COMPARATOR
Intervention: IPS only
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 107
Study: 25980737

Group type: COMPARATOR
Intervention: Standard RDT training
Number of subjects: 29223

Group type: EXPERIMENTAL
Intervention: Health Worker (HW) arm
Number of subjects: 29223

Group type: EXPERIMENTAL
Intervention: Health Worker-Patient (HWP) arm
Number of subjects: 29223
Study: 23371961

Group type: EXPERIMENTAL
Intervention: Steroid-sensitive nephrotic syndrome
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cox regression model
Number of subjects: 166
Study: 21612513

Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse diode (SDM) laser (810 nm)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Double-frequency neodymium YAG (Nd:YAG) laser (532 nm)
Number of subjects: 33
Study: 19307442

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3% policocanol foam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon dioxide foam
Number of subjects: 0
Study: 17845617

Group type: EXPERIMENTAL
Intervention: New combined pruritus scale (features of behaviour and severity-based scales with visual analogue scale)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Severity scale
Number of subjects: 166

Group type: COMPARATOR
Intervention: Numerical scale
Number of subjects: 166

Group type: COMPARATOR
Intervention: Behaviour scale
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Independent scores by two owners
Number of subjects: 166
Study: 15519020

Group type: EXPERIMENTAL
Intervention: Stenotic aortic valves
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control valves
Number of subjects: 97
Study: 11816442

Group type: COMPARATOR
Intervention: Pentostam (sodium stibogluconate, GlaxoWellcome, London)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Generic sodium stibogluconate (SSG) (International Dispensary Association, Amsterdam)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: HIV co-infected VL patients
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: HIV-positive patients
Number of subjects: 199
Study: 9747023

Group type: EXPERIMENTAL
Intervention: Peer counselor support
Number of subjects: 36

Group type: COMPARATOR
Intervention: No peer counselor support (Control)
Number of subjects: 36
Study: 7805356

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1500 mg)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (800 or 1000 mg)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (400 or 500 mg)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Comparators (spectinomycin, thiamphenicol, ampicillin, or amoxicillin plus probenecid)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil
Number of subjects: 567

Group type: COMPARATOR
Intervention: Standard drugs
Number of subjects: 567
Study: 3189218

Group type: EXPERIMENTAL
Intervention: Calcium citrate and malic acids (CCM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 12
Study: 4902494

Group type: EXPERIMENTAL
Intervention: 5% local guanethidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 0
Study: 29550525

Group type: EXPERIMENTAL
Intervention: Active tDCS treatment (1 mA, 3 sessions per week for 6 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 26
Study: 27530996

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention delivered by trained health professionals, consisting of up to four sessions tailored to patient symptoms and distress.
Number of subjects: 902

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 902
Study: 25842223

Group type: EXPERIMENTAL
Intervention: Injectable procaine benzylpenicillin‐gentamicin
Number of subjects: 2333

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 2333

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 2333
Study: 23850318

Group type: EXPERIMENTAL
Intervention: Personalized antiplatelet therapy according to CYP2C19 phenotype
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional antiplatelet treatment
Number of subjects: 600
Study: 21596876

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 μg/kg/min (group HI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Remifentanil 0.05 μg/kg/min (group LO)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg/kg at induction followed by 10 mg/kg/h (group HM)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (group HM)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 19101632

Group type: EXPERIMENTAL
Intervention: Itopride hydrochloride
Number of subjects: 0
Study: 16467656

Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan (160 mg)
Number of subjects: 0
Study: 12865453

Group type: COMPARATOR
Intervention: Bilateral oophorectomy
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Other gynecologic surgeries
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Surgery to remove some ovarian tissue
Number of subjects: 1124
Study: 10853168

Group type: EXPERIMENTAL
Intervention: 5 degrees lateral‐wedged insole
Number of subjects: 17

Group type: COMPARATOR
Intervention: No insole (control condition)
Number of subjects: 17
Study: 9359709

Group type: EXPERIMENTAL
Intervention: Recombinant herpes simplex virus type 2 glycoproteins D and B vaccine in MF59 adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: MF59 alone (placebo)
Number of subjects: 0
Study: 8269444

Group type: EXPERIMENTAL
Intervention: Low-dose bisoprolol/HCTZ 6.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy and placebo
Number of subjects: 0
Study: 3946169

Group type: EXPERIMENTAL
Intervention: Oral amiodarone (30 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral amiodarone
Number of subjects: 50
Study: 31499247

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced EUS
Number of subjects: 101

Group type: COMPARATOR
Intervention: Unenhanced EUS
Number of subjects: 101
Study: 30461306

Group type: EXPERIMENTAL
Intervention: Avelumab in combination with chemoradiotherapy (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in combination with chemoradiotherapy (CRT)
Number of subjects: 0
Study: 28213776

Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (TCI) sedation endoscopy (TCI-DISE)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Conventional DISE (C-DISE)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (TCI-DISE)
Number of subjects: 173
Study: 25127514

Group type: EXPERIMENTAL
Intervention: Modified spinal mobilisation with leg movement (SMWLM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 22878857

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for anxiety disorders
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care by the doctor
Number of subjects: 124
Study: 22092126

Group type: COMPARATOR
Intervention: Fentanyl 0 mcg/kg (F0)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 mcg/kg (F1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 mcg/kg (F1.5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 mcg/kg (F2)
Number of subjects: 60